The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 354:2829-2830 June 29, 2006 Number 26
NextNext

Fondaparinux versus Enoxaparin in Acute Coronary Syndromes

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
 by The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators
-PubMed Citation
To the Editor: The authors of the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS-5) study (April 6 issue)1 point out that despite the presence or absence of administration of unfractionated heparin, bleeding rates were significantly lower with fondaparinux than with enoxaparin in patients with acute coronary syndromes. However, the authors do not fully evaluate the significant difference between patients who received unfractionated heparin after randomization in the enoxaparin group and those who did so in the fondaparinux group (31.2 percent and 22.0 percent, respectively; P<0.001) (Table 1 in the article).

Of the patients who underwent percutaneous coronary . . . [Full Text of this Article]


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.